If you experience significant nausea at 4mg, your provider might keep you at that dose longer before increasing
What is the regulatory status of Retatrutide
Back in 2018, most of its earnings came from generics, with only a small share driven by innovation. Between 2025 and 2027, the company expects to bring dozens of major breakthroughs to market from GLP-1 therapies for obesity and diabetes to next-generation oncology treatments. Source: *Opinions are my own To view or add a comment, sign in Big Pharma News: Pfizer is set to acquire Metsera in a deal worth up to $4.9B Why it matters: $47.50/share upfront + $22.50/share tied to milestones Lead candidate MET-097i (GLP-1 therapy) showed 11.3% weight loss in 12 weeks Pipeline includes monthly amylin-based injections + oral obesity drugs Puts Pfizer head-to-head with Lilly & Novo Nordisk in the obesity race This move highlights the booming obesity drug market and pharmas growing appetite for metabolic innovation
doi: 10.1016/S0140-6736(21)00213-0 234 WildingJPHBatterhamRLCalannaSDaviesMVan GaalLFLingvayIet al
13 14 Beyond lowering fat accumulation in the liver, GLP-1s also improve liver-driven heart risk by decreasing inflammation and reducing levels of enzymes that release artery-damaging particles
When cellular energy (ATP) levels are low and AMP levels are high, AMPK is activated
